Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7535 in Overweight or Obesity
NCT06904105Phase 3Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing HRS-7535 Group with HRS-7535 Placebo Group (2 arms). Primary endpoints: Percentage change in body weight relative to the baseline at 44 weeks and Proportion of participants with a body weight reduction of >= 5% relative to the baseline at 44 weeks. Started Apr 2025; status: completed.
02
Drugs
HRS-7535
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06904105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904105.